Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27824379 | 0.88 | MCHR1 (0.52) | MCHR1L3MBTL3HRH3 | |
| SCHEMBL27847741 | 0.88 | MCHR1 (0.52) | MCHR1L3MBTL3HRH3 | |
| SCHEMBL27580577 | 0.88 | MCHR1 (0.52) | MCHR1L3MBTL3HRH3 | |
| SCHEMBL4194751 | 0.80 | MCHR1 (0.48) | MCHR1L3MBTL3HRH3 | |
| SCHEMBL27781047 | 0.80 | L3MBTL3 (0.60) | MAPTMCHR1L3MBTL3HRH3 | |
| SCHEMBL10206064 | 0.79 | MEN1 (0.53) | MAPTMEN1TP53KMT2APOLB | |
| SCHEMBL2883536 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3HRH3 | |
| SCHEMBL8159119 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3 | |
| SCHEMBL21464535 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3HRH3 | |
| SCHEMBL1196740 | 0.74 | L3MBTL3 (0.50) | MCHR1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | MAPT 3039/4885MEN1 2718/4885TP53 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.